Drugs / Galactomannan
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT05096052 | Apr → Jul 2022 | COVID-19, cytokine release syndrome | Bioxytran Inc. | Unknown | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Galactomannan | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05096052 ↗ |
| Action | Inhibit | “A galectin antagonist prevents viral entry” NCT05096052 ↗ |
| Modality | Other / unclassified | “galectin inhibitor complex carbohydrate” NCT05096052 ↗ |
| Route | Oral | “given orally” NCT05096052 ↗ |